Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Gilead Sciences is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention PURPOSE 2, all published on August 13, 2026.
Last mentioned: Aug 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Gilead Sciences is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention PURPOSE 2, all published on August 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PURPOSE 2. Shared-story counts are live from our verified record — not editorial picks.
NPR report details mixed rollout reviews in Uganda
A syndicated story from Kalisizo, Uganda highlights participant Irene's experience, the drug's six-month protection, and ongoing implementation challenges.
PURPOSE 1 and PURPOSE 2 deliver unprecedented efficacy
An independent monitoring committee concluded lenacapavir was so effective that the randomized phase of both trials was halted early.
A twice-yearly injectable PrEP, lenacapavir showed unprecedented efficacy in the PURPOSE 1 and 2 trials, yet its rollout in Uganda is drawing mixed reviews. For health systems, the drug's adherence-friendly profile must clear delivery, access, and stigma barriers to achieve population-level impact.
PURPOSE 2 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
